Member Profile

Foresee is a Taiwan and U.S.-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.
Foresee’s product portfolio includes late and early-stage programs. CAMCEVI ® 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada and EU, and launched in the U.S. in April 2022. Additionally, U.S. and EU regulatory submissions are under preparation for CAMCEVI ® 21 mg. The phase 3 clinical study of second indication of CAMCEVI® 42 mg,central precocious puberty (CPP), is currently being initiated. FP-025 is a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. The Phase 2 proof-of-concept study in allergic asthmatic patients has been completed with positive outcome. FP-045—a highly selective oral small molecule activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 Fanconi Anemia study is currently being initiated, and a P2 study in pulmonary hypertension group 3 patients is in planning.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2013 Foresee Pharmaceuticals co., Ltd was founded.
   2014 The IND application for FP-001 LMIS 50mg (Leuprolide SIF for prostate cancer, 6-month dosage) approved by the U.S. FDA.
   2016 Acquired the ALDH2 platform technology and its clinical stage products from Aviv Therapeutics, Inc. in the US through technology transfer.
   2017 Announced the results of Phase I human clinical trial for FP-025, an NCE aiming at treating asthma and chronic obstructive pulmonary disease (COPD).
   2018 Officially listed on the counter for Taipei Exchange.
   2019 Authorized Accord Healthcare to distribute FP-001, the drug that treats prostate cancer, in markets except for the US, China, Japan, Taiwan as well as other markets with previously-signed distribution agreements, including the Middle East, Turkey, Israel and Palestine.
   2019 Announced the results of the multinational and multi-center Phase III clinical trial for FP-001 LMIS 25 mg, a new drug product with new formulation for the treatment of prostate cancer.
   2020 Foresee received notification from US FDA that Foresee may proceed with the Phase 2 clinical trials of FP-045 in Fanconi Anemia.
   2020 Foresee entered into an exclusive license agreement with GeneScience Pharmaceuticals (“GenSci”) for Foresee’s novel FP-001 program (Camcevi). GenSci will cover all costs of development, registration, and commercialisation in the territory.
   2021 Foresee received notification from FDA that it may proceed with the Phase 2/3 clinical trials of FP-025 in patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome (ARDS).
   2021 Foresee entered into an exclusive license agreement with Intas Pharmaceuticals (“Intas”) for the US commercialization of Foresee’s novel FP-001 program (Camcevi).
   2021 Foresee announced FDA approval of Camcevi 42mg for the treatment of advanced prostate cancer.
   2022 CAMCEVI 42 mg Injection Emulsion launched in the U.S. for the treatment of advanced prostate cancer.
   2022 Foresee announced EMA approval of CAMCEVI 42 mg for the treatment of advanced prostate cancer.